Results 171 to 180 of about 60,773 (261)

Valorization of bark extracts from Cerrado and Amazon species: phenolic characterization, antioxidant capacity, and photoprotective potential for circular bioeconomy applications

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Tree bark remains an underexploited source of high‐value‐added phenolic compounds with potential circular bioeconomy applications. This work characterized bark extracts from two species of distinct Brazilian biomes, Stryphnodendron adstringens (Cerrado) and Myrcia eximia (Amazon), obtained with three solvents (ethanol, methanol and acetone ...
Mário Sérgio Lorenço, Danilo José Machado de Abreu, Elesandra da Silva Araujo, Uasmim Lira Zidanes, Laise de Jesus dos Santos, Denisse Concepción Vega Villarruel, Elisângela Elena Nunes Carvalho, Fábio Akira Mori   +7 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Semantic Mapping of Public Health Legislation and Emergency Legal Responses Using Natural Language Processing Techniques. [PDF]

Risk Manag Healthc Policy
Wang D, Guan Z, Wu B.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Building community trust through medical education: a four-year descriptive analysis of a national grant program. [PDF]

Front Public Health
Hedges MS, Dent R, Lynch T, de Miguel M.
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Understanding Well-Dying Research in a Rapidly Aging Society: A Text Network and Topic Modeling Analysis of Korean Academic Publications. [PDF]

Healthcare (Basel)
Ku JH, Kim KH.
europepmc   +1 more source

Awareness of the Black Triangle Scheme among healthcare professionals and consumers in Australia: A mixed‐methods study exploring reporting intentions and suggested improvements

British Journal of Clinical Pharmacology, EarlyView.
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes, Sieta T. de Vries, Mohammed Gebre Dedefo, Oliver Frank, Myra Thiessen, Lisa Kalisch Ellett, Christopher Thornton, Renly Lim   +7 more
wiley   +1 more source

People Powering Change: The Movement for a National Plan for Epilepsy. [PDF]

Epilepsy Curr
Bender J, Dean B, Goodkin HP, Kapur J, Lado FA, Lowenstein DH, Mitchell A, Parent JM, Utley K, Weidner L.   +9 more
europepmc   +1 more source